Sugi Predict

Sugi Predict / Compounds / SCHEMBL4209138

SCHEMBL4209138

SCHEMBL4209138

CCCCC(C)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ ALDH1A1 P00352 8/20 0.42
▸ MCHR1 Q99705 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ GBA1 P04062 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ LMNA P02545 1/20 0.39
▸ ALB P02768 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ PLA2G2C Q5R387 1/20 0.38
▸ G6PD P11413 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ PLAU P00749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209136 1.00 CA12 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL31370679 1.00 CA12 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL9060708 0.95 CA12 (0.45) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL9060692 0.95 CA12 (0.45) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL9227919 0.95 CA12 (0.45) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL9144466 0.94 MCHR1 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL8949575 0.94 MCHR1 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL8744438 0.94 MCHR1 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL3443920 0.94 MCHR1 (0.46) CA12CA2CA9ALDH1A1MCHR1
SCHEMBL28915902 0.94 MCHR1 (0.46) CA12CA2CA9ALDH1A1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010352-B1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES GYROS PROTEIN TECH AB (SE) 2023-10-18 — — EP disclosed
EP-4219446-A2 TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION Gyros Protein Technologies AB (SE) 2023-08-02 — — EP disclosed
EP-3408257-B1 LINKER MOLECULE AND USE OF IT IN PROCESS FOR PURIFICATION OF PEPTIDES Belyntic GmbH (DE) 2021-12-22 — — EP disclosed
WO-2021023892-A1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES Belyntic GmbH (DE) 2021-02-11 — — WO disclosed
WO-2017129818-A1 LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) 2017-08-03 — — WO disclosed
US-9240614-B2 Nonaqueous electrolyte solution and electrochemical element using same UBE INDUSTRIES, LTD. (JP) 2016-01-19 — — US disclosed
US-20150182672-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES ABBOTT CARDIOVASCULAR SYSTEMS (US) 2015-07-02 — — US disclosed
US-20150182672-A1 COATINGS FOR IMPLANTABLE MEDICAL DEVICES ABBOTT CARDIOVASCULAR SYSTEMS (US) 2015-07-02 — — US disclosed
US-9067001-B2 Coatings for implantable medical devices ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2015-06-30 — — US disclosed
US-9067001-B2 Coatings for implantable medical devices ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2015-06-30 — — US disclosed
US-20140038907-A1 Coatings For Implantable Medical Devices ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2014-02-06 — — US disclosed
US-8563025-B2 Coatings for implantable medical devices ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2013-10-22 — — US disclosed
EP-2579377-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130071733-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME UBE INDUSTRIES, LTD. (JP) 2013-03-21 — — US disclosed
US-7919075-B1 Coatings for implantable medical devices ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2011-04-05 — — US disclosed
US-20090247743-A1 PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN PFIZER INC 2009-10-01 — — US disclosed
US-5922239-A AN INEXPENSIVE BASE OIL USE AS A WORKING FLUID COMPOSITION FOR A REFRIGERATING MACHINE, HAVING EXCELLENT COMPATIBILITY WITH HYDROFLUOROCARBONS, HYDROLYSIS RESISTANCE, ADEQUATE KINEMATIC VISCOSITY, GOOD FLUIDITY AT LOW TEMPERATURES KAO CORPORATION (JP) 1999-07-13 — — US disclosed
US-5869702-A SPECIALTY OILS FOR REFRIGERATORS KAO CORPORATION (JP) 1999-02-09 — — US disclosed
US-5720895-A CONSISTS OF HYDROFLUOROCARBONS, A REFRIGERATION OIL CONTAINING POLYOL ETHER DERIVATIVES AS A BASE OIL KAO CORPORATION (JP) 1998-02-24 — — US disclosed
EP-0696564-A1 Polyol ether derivatives and production methods therefor KAO CORPORATION (JP) 1996-02-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247743-A1 PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN SCN2A, SCN1A, ORAI2 CA12 2399/4885CA2 106/4885CA9 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.